NO20030304L - Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering - Google Patents

Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering

Info

Publication number
NO20030304L
NO20030304L NO20030304A NO20030304A NO20030304L NO 20030304 L NO20030304 L NO 20030304L NO 20030304 A NO20030304 A NO 20030304A NO 20030304 A NO20030304 A NO 20030304A NO 20030304 L NO20030304 L NO 20030304L
Authority
NO
Norway
Prior art keywords
antagonist
pharmaceutical formulation
new combination
serotonin agonist
serotonin
Prior art date
Application number
NO20030304A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030304D0 (no
Inventor
Sukhwinder Jossan
Bjoern M Nilsson
Kjell S Sakariassen
Jan Svartengren
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO20030304D0 publication Critical patent/NO20030304D0/no
Publication of NO20030304L publication Critical patent/NO20030304L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
NO20030304A 2000-07-21 2003-01-20 Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering NO20030304L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0002754A SE0002754D0 (sv) 2000-07-21 2000-07-21 New pharmaceutical combination formulation and method of treatment with the combination
PCT/SE2001/001651 WO2002008178A1 (en) 2000-07-21 2001-07-19 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation

Publications (2)

Publication Number Publication Date
NO20030304D0 NO20030304D0 (no) 2003-01-20
NO20030304L true NO20030304L (no) 2003-03-12

Family

ID=20280577

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030304A NO20030304L (no) 2000-07-21 2003-01-20 Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering

Country Status (18)

Country Link
EP (1) EP1301476A1 (OSRAM)
JP (1) JP2004504376A (OSRAM)
KR (1) KR100845450B1 (OSRAM)
CN (1) CN1221254C (OSRAM)
AU (2) AU2001282734B2 (OSRAM)
BR (1) BR0112661A (OSRAM)
CA (1) CA2411192A1 (OSRAM)
EA (1) EA006604B1 (OSRAM)
HU (1) HUP0301346A3 (OSRAM)
IL (1) IL154057A0 (OSRAM)
MX (1) MXPA03000548A (OSRAM)
NO (1) NO20030304L (OSRAM)
NZ (1) NZ523216A (OSRAM)
PL (1) PL360309A1 (OSRAM)
SE (1) SE0002754D0 (OSRAM)
WO (1) WO2002008178A1 (OSRAM)
YU (1) YU2603A (OSRAM)
ZA (1) ZA200210234B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
BR0115102B1 (pt) * 2000-11-02 2013-11-26 Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos
CN1321110C (zh) * 2001-06-15 2007-06-13 弗·哈夫曼-拉罗切有限公司 具有5－ht6受体亲和力的4－哌嗪基吲哚衍生物
EP1401812B1 (en) * 2001-06-15 2006-06-28 F. Hoffmann-La Roche Ag 4-piperazinylindole derivatives with 5-ht6 receptor affinity
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
GB0202679D0 (en) * 2002-02-05 2002-03-20 Glaxo Group Ltd Novel compounds
SI1497266T1 (sl) 2002-03-27 2008-10-31 Glaxo Group Ltd Derivati kinolina in njihova uporaba kot ligandi 5-ht6
CL2004000826A1 (es) * 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
EP1558582B1 (en) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
EP1792629A4 (en) 2004-08-25 2010-08-25 Takeda Pharmaceutical MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS
US7713954B2 (en) 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
EP2727585A1 (en) 2006-05-16 2014-05-07 Takeda Pharmaceutical Company Limited In-vivo screening method
US20070293475A1 (en) * 2006-06-20 2007-12-20 Alcon Manufacturing Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma
ATE495737T1 (de) * 2007-08-01 2011-02-15 Esteve Labor Dr Kombination von mindestens zwei 5-ht6-liganden
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND ITS USE
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
JP5579262B2 (ja) 2009-06-15 2014-08-27 武田薬品工業株式会社 ピラジノオキサゼピン誘導体
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用
JPWO2019131902A1 (ja) 2017-12-27 2020-12-10 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
CN111269165A (zh) * 2018-12-05 2020-06-12 中国科学院大连化学物理研究所 一种3-芳基磺酰基吲哚衍生物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII

Also Published As

Publication number Publication date
HUP0301346A3 (en) 2005-05-30
WO2002008178A1 (en) 2002-01-31
EA200300183A1 (ru) 2003-08-28
AU2001282734B2 (en) 2006-10-12
AU8273401A (en) 2002-02-05
KR20030036599A (ko) 2003-05-09
MXPA03000548A (es) 2004-04-05
CN1443162A (zh) 2003-09-17
HK1057536A1 (en) 2004-04-08
EA006604B1 (ru) 2006-02-24
BR0112661A (pt) 2003-06-24
SE0002754D0 (sv) 2000-07-21
CA2411192A1 (en) 2002-01-31
KR100845450B1 (ko) 2008-07-10
NO20030304D0 (no) 2003-01-20
NZ523216A (en) 2005-05-27
YU2603A (sh) 2006-05-25
IL154057A0 (en) 2003-07-31
EP1301476A1 (en) 2003-04-16
PL360309A1 (en) 2004-09-06
JP2004504376A (ja) 2004-02-12
HUP0301346A2 (hu) 2003-08-28
CN1221254C (zh) 2005-10-05
ZA200210234B (en) 2004-03-18

Similar Documents

Publication Publication Date Title
NO20030304D0 (no) Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasöytisk formulering
NO20032797L (no) Substituerte pyridoindoler som serotonin agonister og antagonister
DK1454901T3 (da) Farmaceutiske sammensætninger omfattende tachykininantagonister og en serotoningenoptagelseshæmmer
NO20031744D0 (no) Nye ikke-imadazolforbindelser og farmasöytisk preparat omfattende slike
NO20030418D0 (no) Nytt farmasöytisk preparat
NO20025450L (no) Ny farmasöytisk sammensetning
PT1572707E (pt) Novos derivados fluoroglicosideos aromaticos, farmacos contendo estes compostos e sua utilizacao
EE05400B1 (et) Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks
CY2007013I1 (el) Νεες συνταγοποιησεις αγωνιστου εξεντινης και μεθοδοι χορηγησης αυτων
ATE431145T1 (de) Missbrauchssichere orale opioid-agonist zubereitungen
NO20030471D0 (no) Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20003196L (no) Umiddelbart opplösende doseringsformulering
DE60212044D1 (de) Test der bukkalen Auflösung pharmazeutisch aktiver Stoffe
FI991485A0 (fi) Uusi farmaseuttinen koostumus
DK1263721T3 (da) Farmaceutiske sammensætninger, der indeholder 3-aminoazetidinderivater, nye derivater og fremstilling deraf
NO20033143L (no) Farmasoytisk preparat
ITTO20010008A0 (it) Formulazione farmaceutica
NO20032678L (no) NMDA reseptor agonist farmasöytiske sammensetninger
NO20032517D0 (no) Farmasöytisk preparat inneholdende amlodipinmaleat
DK1119557T3 (da) Indeno-, naphto- og benzocyclohepta-dihydrothiazolderivater, fremstilling deraf og anvendelse deraf som anorektiske medikamenter
NO20041008L (no) Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
NO20041607L (no) Doseringsregime og farmasoytisk preparat for nodprevensjon
NO20022289L (no) Ny anvendelse og nye N-azabisykloamidderivater
DK1230230T3 (da) Derivater af indeno-dihydrothiazol, fremstilling deraf og anvendelse som anorektiske lægemidler
NO20015149L (no) Nytt farmasöytisk preparat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application